Much has been said in recent years about the risks involved in switching from a branded biologic to a biosimilar when a patient has started treatment. This is a controversial matter, due to the special nature of this type of drugs, whose molecular composition, being manufactured with living organisms, can differ even between units of the same product.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
